UPDATE: Piper Jaffray Raises PT to $83 on Regeneron Pharmaceuticals - Regeneron Pharmaceuticals (NASDAQ:REGN)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

A report from Piper Jaffray reiterates its Overweight rating and raises its price target from $73 to $83 on Regeneron Pharmaceuticals (NASDAQ: REGN).The report states, “We expect EYLEA will compete well against Lucentis given the drug's lower price, similar efficacy with fewer monitoring visits and injections. Regeneron expects to end 2011 with >$800 million in cash to launch EYLEA, ZALTRAP in colorectal cancer and ARCALYST to prevent gout flares.”REGN closed Friday at $49.81.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!